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BACKGROUND: Epidermal growth factor receptor (EGFR) promoter methylation may be responsible for the loss of EGFR expression in
neoplastic cells. The primary aim of our study was to verify a possible correlation between EGFR gene promoter methylation and
clinical outcome in metastatic colorectal cancer patients receiving chemotherapy with irinotecan and cetuximab.
METHODS: Colorectal samples from patients treated with irinotecan–cetuximab were analysed for EGFR promoter methylation and
EGFR immunohistochemistry.
RESULTS: Fifty-two patients were analysed. Thirty patients (58%) showed EGFR promoter hypermethylation. In EGFR promoter
methylated and EGFR promoter unmethylated patients, we observed a partial response in 3 (10%) and 13 (59%) patients,
respectively (P¼0.03), progressive disease was obtained in 19 (63%) and 2 (9%) patients, respectively, with EGFR promoter
methylated and EGFR promoter unmethylated tumours (P¼0.0001). Median progression-free survival was 2.4 months in patients
showing EGFR promoter methylated tumours and 7.4 months for those who had EGFR promoter unmethylated tumours (Po0.0001;
Figure 1). Median overall survival was 6.1 months in patients showing EGFR promoter methylated tumours and 17.8 months for those
who had EGFR promoter unmethylated tumours (Po0.0001; Figure 2).
CONCLUSION: EGFR promoter hypermethylation, after confirmation in larger data set, may represent a valuable asset in further studies
investigating EGFR as a therapeutic target in colorectal cancer.
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The molecular mechanisms underlying response or resistance of
epidermal growth factor receptor (EGFR) overexpressing color-
ectal tumours to anti-EGFR compounds are still largely unknown.
However, economic costs and toxicity risks deriving from the use
of anti-EGFR therapeutic options made increasingly essential the
identification of molecular or clinical predictive factors of
response (or resistance) for a better, more accurate, actually
targeted, selection of patients more likely to benefit from such a
treatment approach. The main research areas in this setting have
been focusing on the role of EGFR protein expression, EGFR gene
amplification, EGFR mutations, and markers of EGFR downstream
signalling (Moroni et al, 2005; Benvenuti et al, 2007; Scartozzi et al,
2007, 2009; Di Nicolantonio et al, 2008; Ng and Zhu, 2008;
Loupakis et al, 2009; Perrone et al, 2009). Only after several years
of intense translational research and clinical absence of predictive
factors, the introduction of the K-RAS mutational status seemed to
possess the necessary potential for a full translation into clinical
practice of the concept of targeted therapy in this setting (Di Fiore
et al, 2007; Lievre et al, 2008; Van Cutsem et al, 2009).
However, if on the one hand we are now able to exclude from
anti-EGFR treatment patients with putative refractory colorectal
tumours (i.e., those harbouring a K-RAS mutant status), on the
other hand we are still incapable to accurately select responding
patients among those without K-RAS mutations. In fact clinical
observations suggested that a non-negligible proportion of
patients, usually ranging from 40 to 70%, does not seem to
benefit from the use of anti-EGFR-targeted antibodies although in
the absence of a mutation of the K-RAS gene (i.e., K-RAS wild-type
patients) (Di Fiore et al, 2007; Jonker et al, 2007; Van Cutsem et al,
2007, 2009; Lievre et al, 2008).
We now know that under normal circumstances, EGFR expression
is primarily regulated by the abundance of its m-RNA (Scartozzi
et al, 2007; Van Cutsem et al, 2009). This observation is of particular
relevance if we consider that EGFR m-RNA expression demonstrated
a possible correlation with survival during anti-EGFR treatment (Xu
et al, 1984; Merlino et al, 1985; Vallbo ¨hmer et al,2 0 0 5 ) .A tl e a s t
hypothetically, EGFR promoter silencing may then affect clinical
outcome of patients treated with anti-EGFR strategies through the
inhibition of EGFR m-RNA expression.
Cytosine methylation of promoter-associated CpG islands is an
important epigenetic mechanism of gene silencing that is
frequently observed in cancer, leading to inhibition of gene
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stranscription (Xu et al, 1984; Merlino et al, 1985). Hypermethyla-
tion typically affects tumour-suppressor genes, but can also silence
oncogenes such as COX219 and TERT (Devereux et al, 1999;
Santini et al, 2001; Jones and Baylin, 2002).
Montero et al analysed the presence of EGFR promoter
hypermethylation in a series of cell lines and tissues, suggesting
that EGFR promoter hypermethylation may represent a relevant
event in breast, head and neck, and lung tumours. In this study,
EGFR hypermethylation was observed in none of the 17 colorectal
tumours tested and in 7 of the 17 (24%) normal colon tissue
(Montero et al, 2006). However, in a larger analysis including 63
colorectal tumours we previously demonstrated that EGFR
promoter methylation should not be considered a rare event in
colorectal tumours as this biological phenomenon occurred in as
many as 39% of all cases analysed (Scartozzi et al, 2009).
Based on these considerations, we then hypothesised that EGFR
promoter methylation may be responsible for the loss of EGFR
expression in neoplastic cells, with the consequent loss of the
therapeutic target for anti-EGFR monoclonal antibodies. These
observations may be relevant for clinical outcome prediction with
the use of anti-EGFR treatment strategies and could also indicate
new research perspectives for the introduction of pharmacological
agents able to determine re-expression of the therapeutic target
(EGFR) in this area. The aim of our study was then to verify a
possible correlation between EGFR gene promoter methylation and
clinical outcome in metastatic colorectal cancer patients receiving
chemotherapy with irinotecan and cetuximab. The possible
correlation between EGFR promoter methylation status and EGFR
protein expression was also tested.
PATIENTS AND METHODS
Patients selection
Patients with histologically proven EGFR-positive, K-RAS wild-
type, metastatic, colorectal cancer receiving a combination of
cetuximab and irinotecan after at least one line of previous
chemotherapy were eligible for our analysis. To be eligible,
patients must also have received an irinotecan-based chemother-
apy regimen for at least 6 weeks and must have presented
progression of disease during receipt of this regimen or within 3
months thereafter. All patients received cetuximab at an initial
dose of 400mg per square metre followed by weekly infusions of
250mg per square metre. Irinotecan was administered at a dose of
180mg per square metre every 2 weeks either alone or in
combination with five fluorouracil and leucovorin. Tumour
response was evaluated every 8 weeks by clinicians’ assessment
and according to the Response Evaluation Criteria in Solid
Tumours (RECIST).
Formalin-fixed and paraffin-embedded tumour samples (either
primary site or metastasis or both when available) of colorectal
cancer patients were analysed for EGFR protein expression
(immunohistochemistry) and for EGFR promoter methylation.
EGFR promoter methylation study
Analysis of EGFR promoter methylation was performed following
a DNA Extraction Protocol from paraffin-embedded tissue and a
methylation-specific PCR (MSP). The tumour samples were
processed according to the QIAamp DNA mini Tissue Protocol,
using QIAamp DNA Mini Kit (QIAGEN GmbH, Hilden, Germany).
Before PCR amplification, the DNA extract was treated with
sodium bisulphite as described in the handbook of the ‘EpiTect
Bisulfite Kit’ (QIAGEN GmbH). Bisulphite modification of DNA to
convert all unmethylated cytosines to uracil and then to thymidine
during the subsequent PCR step while leaving the methylated
cytosines unaffected was performed as described by Herman et al
(1996). For PCR amplification, two sets of primers were designed
from nt  130 to  300 (relative to ATG) in the 50-untranslated
region of the human EGFR promoter.
The primer sequences used were 50-TGTTTTGTTTTTTT
GTGTTTTGGTTTGTGT-30 (sense) and 50-CATCCAATCTAAACA
ACAACAACCACCA-30 (antisense) for unmethylated DNA and
50-TGTTTTTTCGCGTTTCGGTTCGCGC-30 (sense) and 50-CGTCTAA
ACGACGACGACCGCCG-30(antisense) for methylated DNA, both
of which amplify B150bp products (Nagothu et al, 2004). The
PCR mixture contained 1  PCR buffer, Minus Mg; 0.2mM dNTP
mixture (each); 1.5mM MgCl2; 0.2mM Primer mix (each); 1.0 unit
Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA, USA);
and bisulphite-modified DNA (of 1ng–2mg) in a final volume of
50ml. Controls without DNA were performed for each set of PCRs.
Each PCR product (30ml) was directly visualised on 10%
acrylamide gels. The gel was stained with ethidium bromide and
photographed under UV illumination. An enzymatically methy-
lated human male genomic DNA (CpGenome Universal Methylated
DNA CHEMICON International) was used as a methylation-
positive control for gene methylation studies and was processed
as above mentioned.
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Figure 1 Kaplan–Meier curves for median progression-free survival
(PFS) of colorectal cancer patients treated with irinotecan and cetuximab
with EGFR promoter methylated (—————) and without EGFR
promoter methylated (———) tumours (2.4 vs 7.4 months, Po0.0001).
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Figure 2 Kaplan–Meier curves for median overall survival (OS) of
colorectal cancer patients treated with irinotecan and cetuximab with EGFR
promoter methylated (—————) and without EGFR promoter
methylated (———) tumours (6.1 vs 17.8 months, Po0.0001).
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Epidermal growth factor receptor (DakoCytomation, Carpinteria,
CA, USA) was evaluated with an immunohistochemistry technique
on 5mm-thick tissue section obtained from paraffin-embedded
specimens fixed in 10% (v/v) neutral buffered formalin, and was
performed using kit EGFR PharmaDx (DakoCytomation) accord-
ing to the manufacturer’s instructions as previously described
(Scartozzi et al, 2004). Briefly, the intensity of EGFR reactivity was
scored using a three-tier system as follows: 1þ (weak intensity:
faint brown membranous staining); 2þ (moderate intensity:
brown membranous staining of intermediate darkness producing
a complete or incomplete circular outline of the neoplastic cell);
3þ (strong intensity: dark brown or black membranous staining
producing a thick outline, complete or incomplete of the
neoplastic cell) (Scartozzi et al, 2004).
Statistical analysis
Statistical analysis was performed with MedCalc package (MedCalc
v9.4.2.0, MedCalc Software, Mariakerke, Belgium).
The association between categorical variables was analysed by
w
2-test. Survival distribution was estimated by the Kaplan–Meier
method. Significant differences in probability of relapsing between
the strata were evaluated by log-rank test.
A significant level of 0.05 was chosen to assess the statistical
significance.
For statistical analysis, overall survival (OS) and progression-
free survival (PFS) were defined, respectively, as the interval
between the start of cetuximab and irinotecan therapy to death or
last follow-up visit and as the interval between the start of
cetuximab and irinotecan therapy to clinical progression or death
or last follow-up visit if not progressed.
RESULTS
Fifty-two metastatic colorectal cancer patients were eligible for our
analysis: 33 patients were males (63%) and 19 females (37%),
median age at diagnosis was 62 years (range 35–80) (Table 1).
In 27 patients (52%), the EGFR promoter methylation study was
conducted on primary colorectal tumours, in 21 cases (40%) both
primary tumours and corresponding metastasis (liver metastases
in all cases) were available for analysis, while in 4 cases (8%) only
the metastatic site (liver metastases in all cases) was investigated.
For study purposes when results for EGFR methylation status in
primary colorectal tumours and corresponding metastases resulted
conflicting, only the methylation status in metastases was
considered biologically relevant. Although data guiding this choice
are lacking the purpose of the study was to assess the correlation
between EGFR gene promoter methylation and clinical outcome in
patients treated with cetuximab for metastatic disease. Therefore,
we can hypothesise that the methylation status in metastases is
more relevant for response/resistance to such treatment approach.
Globally, 30 patients (58%) showed EGFR promoter hyper-
methylation either in primary colorectal cancer or in metastasis. In
12 cases (40%), EGFR promoter methylation resulted biallelic,
whereas in the remaining 18 tumours (60%) only one allele
resulted methylated. This two groups of patients (i.e., those with
monoallelic EGFR promoter methylation and those with mono-
allelic EGFR promoter methylation resulted) comparable for all
main clinical characteristics and experienced a similar clinical
outcome during treatment with cetuximab (Table 2). Among the 21
patients in whom both primary site and metastases were available
for EGFR methylation study, EGFR methylation status of primary
tumour was in accordance with that of metastasis in 16 patients
(76%): 4 patients with EGFR promoter hypermethylation and 12
patients with unmethylated tumours. In the remaining five patients
(24%), there was not concordance in EGFR promoter methylation
status between primary tumour and metastasis. In particular, two
patients with EGFR hypermethylation in the primary tumour
showed unmethylated EGFR in metastasis and three metastases
showing EGFR promoter hypermethylation derived from un-
methylated EGFR primary tumours.
Table 1 Patients characteristics and main study results
Whole
group
(n¼52)
EGFR
unmet
(n¼22, 42%)
EGFR
met
(n¼30, 58%) P-value
Age (range) 62 (35–80) 63 (35–78) 62 (37–80)
Sex
Males 33 (63%) 15 (68%) 18 (66%)
Females 19 (37%) 7 (32%) 12 (34%)
Previous lines of treatment
1 6 (12%) 4 (18%) 2 (7%)
2–3 46 (88%) 18 (82%) 28 (93%)
Treatment
mFOLFIRI+cetuximab 18 (35%) 8 (36%) 10 (33%)
Irinotecan+cetuximab 34 (65%) 14 (68%) 20 (67%)
Response rate
PR 16 (31%) 13 (59%) 3 (10%) 0.03
SD 15 (29%) 7 (32%) 8 (27%)
PD 21 (40%) 2 (9%) 19 (63%) 0.0001
Median PFS (months) 3.2 7.4 2.4 o0.0001
Median OS (months) 13.3 17.8 6.1 o0.0001
Abbreviations: mFOLFIRI¼modified FOLFIRI (irinotecan 180mgsqm
 1 d1, 5FU
bolus 400mgsqm
 1 d1, 5FU 2400mgsqm
 1 continuous infusion for 46h);
PR¼partial remission; SD¼stable disease; PD¼progressive disease; PFS¼progres-
sion-free survival; OS¼overall survival; EGFR¼epidermal growth factor receptor.
Only statistically significant P-values have been indicated.
Table 2 Patients characteristics and main results according to EGFR
promoter methylation status (monoallelic vs biallelic EGFR promoter
methylation)
EGFR
monoallelic
(n¼18, 60%)
EGFR
biallelic
(n¼12, 40%) P-value
Age (range) 61 (35–78) 62 (37–80)
Sex
Males 11 (61%) 7 (58%)
Females 7 (39%) 5 (42%)
Previous lines of treatment
1 1 (5%) 1 (8%)
2–3 17 (95%) 11 (92%)
Treatment
mFOLFIRI+cetuximab 6 (33%) 4 (33%)
Irinotecan+cetuximab 12 (66%) 8 (66%)
Response rate
PR 2 (11%) 1(8%) Ns
SD 5 (28%) 3 (25%) Ns
PD 11 (61%) 8 (67%) Ns
Median PFS (months) 2.2 2.4 Ns
Median OS (months) 5.9 6.1 Ns
Abbreviations: mFOLFIRI¼modified FOLFIRI (irinotecan 180mgsqm
 1 d1, 5FU
bolus 400mgsqm
 1 d1, 5FU 2400mgsqm
 1 continuous infusion for 46h);
PR¼partial remission; SD¼stable disease; PD¼progressive disease; PFS¼progres-
sion-free survival; OS¼overall survival; EGFR¼epidermal growth factor receptor.
No statistically significant differences could be noticed among the two groups of
patients.
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EGFR promoter methylated and EGFR promoter unmethylated
groups of patients. In particular, no differences were noticed for
sex, age at diagnosis, and previous lines of chemotherapy (Table 1).
On the contrary in EGFR promoter methylated and EGFR
promoter unmethylated patients, we observed a partial response
in 3 (10%) and 13 (59%) patients, respectively (P¼0.03),
progressive disease was obtained in 19 (63%) and 2 (9%) patients,
respectively, with EGFR promoter methylated and EGFR promoter
unmethylated tumours (P¼0.0001). No statistically significant
differences were noticed for stable disease (Table 1). Median PFS
was 2.4 months in patients showing EGFR promoter methylated
tumours and 7.4 months for those who had EGFR promoter
unmethylated tumours (Po0.0001; Figure 1). Median OS was 6.1
months in patients showing EGFR promoter methylated tumours
and 17.8 months for those who had EGFR promoter unmethylated
tumours (Po0.0001; Figure 2).
Overall, EGFR immunohistochemical assessment resulted posi-
tive in 36 patients (69%).
Lack of EGFR protein expression was observed in nine EGFR
promoter methylated tumours (30%) and in seven EGFR promoter
unmethylated tumours (32%).
DISCUSSION
The expanding role of anti-EGFR therapeutic modalities for the
treatment of colorectal cancer patients, along with the growing
number of cases potentially requiring such a treatment approach,
made the need for a correct and reliable identification of
responding tumours increasingly crucial.
Unfortunately beside K-RAS mutational status and although the
intense ongoing translational research no clear indications for
further predictive molecular markers are available at the moment.
Transcriptional silencing of tumour-suppressor genes, by
methylation of CpG dinucleotide-rich areas in gene promoter, is
one of the major epigenetic mechanisms leading to inactivation
(and thus to lack of m-RNA expression) of important growth
control genes (Herman and Baylin, 2003). However, data about
EGFR gene silencing by promoter methylation are substantially
lacking and may help clarifying the role of this epigenetic
mechanism on colorectal cancer biology (Scartozzi et al, 2009).
The implications for anti-EGFR treatment options are also
relevant. Loss of EGFR expression consequent to promoter
methylation may underlie loss of the therapeutic target and may
then indicate both a predictive factor for anti-EGFR therapy and
new research perspectives for the use of demethylating agents.
In our analysis, EGFR promoter methylation was evident in 30
patients (58%), thus indicating that this biological phenomenon
should not be considered an infrequent event in colorectal
tumours and confirming our previous report. Moreover, patients
presenting an EGFR promoter methylated tumour experienced in
fact a worse clinical outcome thus confirming our hypothesis of a
role for EGFR promoter methylation in determining the efficacy of
anti-EGFR-targeted monoclonal antibodies.
A clear correspondence between EGFR promoter methylation
and loss of EGFR immunohistochemical expression was not
evident. It is then unlikely that loss of EGFR expression as
determined with immunohistochemistry may be related to EGFR
promoter hypermethylation. When we consider that EGFR
promoter methylation represents a predictive factor for cetuximab
treatment in our series, the observation of a lack of concordance of
this biological phenomenon with EGFR immunohistochemistry
expression seems clinically sound and in accordance to previous
data, indicating that loss of EGFR immunohistochemical expres-
sion should not be considered a predictive factor for anti-EGFR
monoclonal antibodies activity (Cunningham et al, 2004). How-
ever, it is also likely that immunohistochemistry evaluation of
EGFR protein expression may not be accurate enough to detect
loss of EGFR protein in cancer tissues, thus compromising data
analysis and interpretation in this setting (Atkins et al, 2004).
It is also important to note that only in 12 patients (40%) EGFR
methylation resulted biallelic, and methylation of only one allele
could not be sufficient to actually silence the gene, inducing a total
loss of protein production. On the other hand, EGFR promoter
methylation of one allele seemed able to determine resistance to
anti-EGFR therapy in our series and we could not find substantial
difference among the two groups of patients with EGFR promoter
methylation (i.e., those with monoallelic EGFR promoter methyla-
tion and those with monoallelic EGFR promoter methylation).
Therefore, we can speculate that other relevant biological
mechanisms, such as loss of heterozygosity, may contribute to
loss of gene function along with monoallelic promoter methylation
in tumour tissues.
However, the relatively small number of patients analysed in our
series represents a clear limitation for a definitive conclusion
about the role of EGFR promoter methylation in determining
response to anti-EGFR treatments, and our findings should be
considered speculative. A further possible limiting factor is
represented by the proportion of patients with a concordant EGFR
methylation status between primary tumour and metastases (76%).
This observation is however in line with our previous observation
of a concordance for EGFR methylation status in 69% of patients
with metastatic colorectal cancer.
The possible role of EGFR promoter methylation in EGFR gene
silencing could provide new clues in anti-EGFR biological agents
use optimisation. It has been in fact reported that treatment with
the demethylating agent decitabine may result in the re-expression
of EGFR in two breast cancer cell lines, in which EGFR
transcription was abolished by EGFR promoter hypermethylation.
Both cell lines are relatively resistant to killing by the EGFR
inhibitor gefitinib; however, after co-treatment with decitabine and
gefitinib, a significant effect on the induction of apoptosis was
observed (Montero et al, 2006).
Combined approaches targeting EGFR dysfunction may be
useful for patients with EGFR methylated tumours and could
represent the basis for prospective studies aiming to compare
clinical response with EGFR directed therapeutic agents. Strategies
have been developed that combine treatments with drugs
reactivating silenced gene expression (such as demethylating
drugs) with secondary agents that target the re-expressed genes
and/or reconstituted signal transduction pathways (Karpf and
Jones, 2002). This treatment approach looks appealing for further
dedicated trials in EGFR promoter methylated tumours.
We believe that EGFR promoter hypermethylation, after
confirmation in larger data set, may represent a valuable and
important asset to be considered in further studies investigating
the role of EGFR as a therapeutic target in colorectal cancer
patients.
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